Sleep Disturbances and Their Association With Serum Magnesium Level in Patients With Major Depressive Disorder

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07198477

Enrollment

Registered

2025-09-30

Start date

2026-08-30

Completion date

2027-12-30

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Sleep Disturbances

Keywords

sleep disturbances

Brief summary

This cross-sectional study investigates the relationship between serum magnesium levels and the presence of sleep disturbances among patients with major depressive disorder (MDD).

Detailed description

Major depressive disorder is a highly prevalent psychiatric condition often accompanied by disabling sleep disturbances, including insomnia and hypersomnia. Evidence suggests that magnesium, a vital trace element involved in neurotransmission, stress response, and circadian regulation, may play a crucial role in both mood and sleep. Low serum magnesium levels have been linked to increased depressive symptom severity and disturbed sleep quality. This study seeks to explore whether hypomagnesemia can serve as a biological contributor to sleep dysfunction in MDD. By employing the Beck Depression Inventory-II (BDI-II) and the Pittsburgh Sleep Quality Index (PSQI), as well as laboratory measurement of serum magnesium levels, the study aims to determine whether lower magnesium is significantly associated with greater depressive burden and poor sleep outcomes. The findings may help validate magnesium as a biomarker for early screening and risk stratification in psychiatric care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of major depressive disorder age 18 years and older Ability to complete questionnaires (BDI-II and PSQI; validated Arabic versions) Willing to participate and provide informed consent

Exclusion criteria

* hronic renal failure or metabolic disorders affecting magnesium balance Current use of medications known to significantly interfere with serum magnesium (e.g., long-term diuretics, proton pump inhibitors) unless stable and documented Presence of other comorbid psychiatric disorders Cognitive impairment or language difficulties preventing questionnaire completion

Design outcomes

Primary

Measure	Time frame	Description
change in the level of serum magnesium level	Baseline	Serum magnesium concentration (mmol/L) measured by atomic absorption spectrophotometry for the patients.

Outcome results